Glial modulators as potential treatments of psychostimulant abuse.
Glia (including astrocytes, microglia, and oligodendrocytes), which constitute the majority of cells in the brain, have many of the same receptors as neurons, secrete neurotransmitters and neurotrophic and neuroinflammatory factors, control clearance of neurotransmitters from synaptic clefts, and are intimately involved in synaptic plasticity. Despite their prevalence and spectrum of functions, appreciation of their potential general importance has been elusive since their identification in the mid-1800s, and only relatively recently have they been gaining their due respect. This development of appreciation has been nurtured by the growing awareness that drugs of abuse, including the psychostimulants, affect glial activity, and glial activity, in turn, has been found to modulate the effects of the psychostimulants. This developing awareness has begun to illuminate novel pharmacotherapeutic targets for treating psychostimulant abuse, for which targeting more conventional neuronal targets has not yet resulted in a single, approved medication. In this chapter, we discuss the molecular pharmacology, physiology, and functional relationships that the glia have especially in the light in which they present themselves as targets for pharmacotherapeutics intended to treat psychostimulant abuse disorders. We then review a cross section of preclinical studies that have manipulated glial processes whose behavioral effects have been supportive of considering the glia as drug targets for psychostimulant-abuse medications. We then close with comments regarding the current clinical evaluation of relevant compounds for treating psychostimulant abuse, as well as the likelihood of future prospects.
Virginia Commonwealth University, Richmond, Virginia, USA. Electronic address: pbeardsl@vcu.edu.
Patrick M
PM
Beardsley
Virginia Commonwealth University, Richmond, Virginia, USA.
Kurt F
KF
Hauser
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D000697:Central Nervous System Stimulants / Q000009:adverse effects; D006801:Humans; D008911:Minocycline / Q000008:administration & dosage / Q000378:metabolism; D009457:Neuroglia / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D011725:Pyridines / Q000008:administration & dosage / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000378:metabolism*; D016896:Treatment Outcome; D007212:Indolizines; D011720:Pyrazoles
D000697:Central Nervous System Stimulants; D008911:Minocycline; D011725:Pyridines; C038366:ibudilast; D007212:Indolizines; D011720:Pyrazoles
Astroglia; Cocaine; Glia; Medication; Methamphetamine; Microglia